trihexyphenidyl has been researched along with Abetalipoproteinemia in 1 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Abetalipoproteinemia: An autosomal recessive disorder of lipid metabolism. It is caused by mutation of the microsomal triglyceride transfer protein that catalyzes the transport of lipids (TRIGLYCERIDES; CHOLESTEROL ESTERS; PHOSPHOLIPIDS) and is required in the secretion of BETA-LIPOPROTEINS (low density lipoproteins or LDL). Features include defective intestinal lipid absorption, very low serum cholesterol level, and near absent LDL.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Critchley, EM | 1 |
| Clark, DB | 1 |
| Wikler, A | 1 |
1 other study available for trihexyphenidyl and Abetalipoproteinemia
| Article | Year |
|---|---|
An adult form of acanthocytosis.
Topics: Abetalipoproteinemia; Adult; Ataxia; Diazepam; Female; Haloperidol; Humans; Huntington Disease; Hydr | 1967 |